Rahhal Alaa Abdullah, Awaisu Ahmed, Tawengi Kawthar M, AbuYousef Safae, Mekideche Lylia
Qatar University, Doha, Qatar.
Int J Clin Pharm. 2017 Oct;39(5):1070-1083. doi: 10.1007/s11096-017-0526-3. Epub 2017 Aug 19.
Background Digoxin is a cardiac glycoside that is recommended by clinical practice guidelines to be used in patients with heart failure with reduced ejection fraction (HFrEF) who still have persistent symptoms despite optimal medical therapy. However, this recommendation is based on limited and old trial data. Moreover, pharmacoepidemiologic studies are important in determining the prevalence of digoxin use and factors influencing this. Objective This study aimed to determine the prevalence and the predictors of digoxin utilization among patients with HFrEF with or without atrial fibrillation (AF) in Qatar. Setting Heart Hospital, a specialized tertiary care center in Qatar. Methods A retrospective observational study was conducted using Cerner electronic medical records. Subjects included 736 patients admitted between January 1, 2013 and December 31, 2014 with the diagnosis of HFrEF with or without AF. Two groups of patients were studied: digoxin users and digoxin non-users at index hospitalization until discharge. Univariate and multivariate binary logistic regression analyses were conducted to determine the predictors of digoxin prescription. Data analyses were performed using IBM SPSS version 23.0. Main outcome measures Prevalence and predictors of digoxin prescriptions among HFrEF patients measured in percentages and odds rations, respectively. Results A total of 736 patients who met the inclusion criteria were analyzed for digoxin prevalence, including 80 patients (11%) who were newly prescribed digoxin during the index hospitalization. After adjusting for patient demographics and clinical characteristics, the use of thiazide diuretics (aOR = 10.14, CI 2.31-44.6, p value = 0.002), concurrent AF (aOR = 8.2, CI 3.11-21.7, p < 0.001), and an ejection fraction (EF) <25% (aOR = 3.2, CI 1.5-6.8, p value = 0.002) significantly predicted digoxin prescriptions among patients with HFrEF. Conclusion The rate of digoxin prescription among patients with HFrEF in Qatar is relatively low. The strongest predictors of digoxin use in HFrEF patients were the concomitant use of thiazide diuretics and concurrent diagnosis of AF. The findings may potentially serve as useful guides for the rational utilization of digoxin in patients with HFrEF.
地高辛是一种强心苷类药物,临床实践指南推荐用于射血分数降低的心力衰竭(HFrEF)患者,这些患者尽管接受了最佳药物治疗,但仍有持续症状。然而,这一推荐是基于有限且陈旧的试验数据。此外,药物流行病学研究对于确定地高辛的使用 prevalence 以及影响其使用的因素很重要。
本研究旨在确定卡塔尔有或无房颤(AF)的 HFrEF 患者中地高辛的使用 prevalence 及其预测因素。
卡塔尔的一家专业三级护理中心心脏医院。
使用 Cerner 电子病历进行回顾性观察研究。研究对象包括 2013 年 1 月 1 日至 2014 年 12 月 31 日期间因诊断为有或无 AF 的 HFrEF 而入院的 736 例患者。研究了两组患者:直至出院时在首次住院期间使用地高辛的患者和未使用地高辛的患者。进行单因素和多因素二元逻辑回归分析以确定地高辛处方的预测因素。使用 IBM SPSS 23.0 版进行数据分析。
分别以百分比和比值比衡量 HFrEF 患者中地高辛处方的 prevalence 和预测因素。
共分析了 736 例符合纳入标准的患者的地高辛 prevalence,其中 80 例(11%)在首次住院期间新开具了地高辛。在调整患者人口统计学资料和临床特征后,噻嗪类利尿剂的使用(调整后比值比[aOR]=10.14,可信区间[CI]2.31 - 44.6,p 值 = 0.002)、并发 AF(aOR = 8.2,CI 3.11 - 21.7,p < 0.001)以及射血分数(EF)<25%(aOR = 3.2,CI 1.5 - 6.8,p 值 = 0.002)显著预测了 HFrEF 患者的地高辛处方。
卡塔尔 HFrEF 患者中地高辛处方率相对较低。HFrEF 患者使用地高辛的最强预测因素是噻嗪类利尿剂同时使用和并发 AF 诊断。这些发现可能为 HFrEF 患者合理使用地高辛提供有用指导。